|
CN107648668B
(zh)
|
2010-10-06 |
2021-06-18 |
哈佛学院董事会 |
用于基于材料的细胞疗法的可注射的成孔水凝胶
|
|
DK2838515T3
(da)
|
2012-04-16 |
2020-02-24 |
Harvard College |
Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser
|
|
US9695212B2
(en)
|
2012-12-13 |
2017-07-04 |
Aduro Biotech, Inc. |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
EP2943565B1
(en)
|
2013-01-14 |
2018-03-28 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
|
|
US9840533B2
(en)
|
2013-04-29 |
2017-12-12 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
WO2014179760A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
|
PE20160080A1
(es)
|
2013-05-18 |
2016-02-21 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
US10176292B2
(en)
|
2013-07-31 |
2019-01-08 |
Memorial Sloan-Kettering Cancer Center |
STING crystals and modulators
|
|
EP3137105A4
(en)
|
2014-04-30 |
2017-12-27 |
President and Fellows of Harvard College |
Combination vaccine devices and methods of killing cancer cells
|
|
CR20160564A
(es)
|
2014-06-04 |
2017-01-20 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos cíclicos como moduladores de sting
|
|
EP3546473B1
(en)
|
2014-12-16 |
2025-12-10 |
Kayla Therapeutics |
Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EA035817B1
(ru)
|
2015-03-10 |
2020-08-14 |
Адуро Байотек, Инк. |
Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
|
|
KR102873947B1
(ko)
|
2015-05-07 |
2025-10-22 |
베이롤 칼리지 오브 메드신 |
수지상 세포 면역요법
|
|
WO2017011444A1
(en)
*
|
2015-07-13 |
2017-01-19 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating b cell cancers
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
KR102222186B1
(ko)
|
2015-08-13 |
2021-03-03 |
머크 샤프 앤드 돔 코포레이션 |
Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
|
|
US10322177B2
(en)
|
2015-10-07 |
2019-06-18 |
Nant Holdings Ip, Llc |
Activation of immune-related signaling pathways in cells via optofection
|
|
JP2018534295A
(ja)
|
2015-10-28 |
2018-11-22 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
|
|
CN107849084B
(zh)
|
2015-12-03 |
2021-09-14 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为sting调节剂的环状嘌呤二核苷酸
|
|
KR102789862B1
(ko)
|
2016-01-11 |
2025-04-03 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
|
|
US10723756B2
(en)
|
2016-01-11 |
2020-07-28 |
Innate Tumor Immunity Inc. |
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
|
EP3402498A1
(en)
|
2016-01-11 |
2018-11-21 |
Synlogic, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
|
NZ746112A
(en)
|
2016-03-18 |
2023-01-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
JP2019510802A
(ja)
*
|
2016-04-07 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
タンパク質調節物質として有用な複素環アミド
|
|
PT3440076T
(pt)
|
2016-04-07 |
2022-07-29 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas úteis como modeladores de proteína
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
IL264557B2
(en)
|
2016-08-02 |
2024-01-01 |
Harvard College |
Biological agents for regulating immune responses
|
|
AU2017321609C1
(en)
|
2016-08-30 |
2023-11-09 |
Dana-Farber Cancer Institute, Inc. |
Drug delivery compositions and uses thereof
|
|
US20190345191A1
(en)
|
2016-08-31 |
2019-11-14 |
Innate Tumor Immunity, Inc. |
Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
|
|
PT3523287T
(pt)
|
2016-10-04 |
2021-10-06 |
Merck Sharp & Dohme |
Compostos de benzo[b]tiofeno como agonistas de sting
|
|
US11001605B2
(en)
|
2016-10-07 |
2021-05-11 |
Biolog Life Science Institute Gmbh & Co. Kg |
Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
|
|
PE20210255A1
(es)
|
2016-12-01 |
2021-02-10 |
Takeda Pharmaceuticals Co |
Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
|
|
WO2018118665A1
(en)
*
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Cyclic dinucleotide sting agonists for cancer treatment
|
|
CN110167566A
(zh)
*
|
2016-12-21 |
2019-08-23 |
弗莱德哈钦森癌症研究中心 |
治疗实体瘤细胞和逃避变体的支架
|
|
BR112019013863A2
(pt)
|
2017-01-06 |
2020-03-03 |
Synlogic Operating Company, Inc. |
Micro-organismos programados para produzir moduladores imunes e terapêuticos anticâncer em células tumorais
|
|
CN110234403A
(zh)
*
|
2017-01-27 |
2019-09-13 |
詹森生物科技公司 |
作为sting激动剂的环状二核苷酸
|
|
US11021511B2
(en)
|
2017-01-27 |
2021-06-01 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
BR112019015797A2
(pt)
|
2017-02-01 |
2020-03-17 |
Modernatx, Inc. |
Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
|
|
JP2018131427A
(ja)
*
|
2017-02-17 |
2018-08-23 |
国立研究開発法人理化学研究所 |
免疫細胞の制御技術
|
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
|
MX2019012295A
(es)
|
2017-04-14 |
2020-02-07 |
Tollnine Inc |
Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
|
|
US11466047B2
(en)
|
2017-05-12 |
2022-10-11 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
US11969499B2
(en)
|
2017-06-16 |
2024-04-30 |
William Marsh Rice University |
Hydrogel delivery of sting immunotherapy for treatment cancer
|
|
EP3431484A1
(en)
*
|
2017-07-21 |
2019-01-23 |
Ludwig-Maximilians-Universität München |
A fluorescent cyclic dinucleotide and its use in methods of identifying substances having an ability to modulate the cgas/sting pathway
|
|
RU2020109328A
(ru)
|
2017-08-04 |
2021-09-06 |
Мерк Шарп И Доум Корп. |
Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
|
|
JP2020530838A
(ja)
*
|
2017-08-04 |
2020-10-29 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
|
|
US10947263B2
(en)
*
|
2017-08-31 |
2021-03-16 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
WO2019046511A1
(en)
*
|
2017-08-31 |
2019-03-07 |
Sperovie Biosciences, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
|
|
JP7208225B2
(ja)
*
|
2017-08-31 |
2023-01-18 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
|
AU2018344902B2
(en)
|
2017-10-05 |
2021-06-03 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING) useful in treating HIV
|
|
EP3691640A1
(en)
*
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Methods for administering sting agonists
|
|
CA3077337A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting)
|
|
KR20200098511A
(ko)
|
2017-11-10 |
2020-08-20 |
다케다 야쿠힌 고교 가부시키가이샤 |
Sting 조절제 화합물, 및 제조 및 사용 방법
|
|
WO2019123339A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
EP3728283B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
EP3727401A4
(en)
|
2017-12-20 |
2022-04-06 |
Merck Sharp & Dohme Corp. |
CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
|
|
WO2019134707A1
(zh)
*
|
2018-01-08 |
2019-07-11 |
成都先导药物开发股份有限公司 |
一种免疫调节剂
|
|
CA3093849A1
(en)
|
2018-03-23 |
2019-09-26 |
Codiak Biosciences, Inc. |
Extracellular vesicles comprising sting-agonist
|
|
WO2019180683A1
(en)
|
2018-03-23 |
2019-09-26 |
Takeda Pharmaceutical Company Limited |
Sting modulator compounds with sulfamate linkages, and methods of making and using
|
|
EP3774765A4
(en)
|
2018-04-03 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
|
JP7326319B2
(ja)
*
|
2018-04-03 |
2023-08-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
|
|
WO2019195658A1
(en)
|
2018-04-05 |
2019-10-10 |
Dana-Farber Cancer Institute, Inc. |
Sting levels as a biomarker for cancer immunotherapy
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
JP7570235B2
(ja)
|
2018-05-25 |
2024-10-21 |
インサイト・コーポレイション |
Ｓｔｉｎｇ活性化剤としての三環式複素環式化合物
|
|
BR112020024605A2
(pt)
|
2018-06-01 |
2021-04-06 |
Eisai R&D Management Co., Ltd. |
Métodos para o tratamento de câncer de bexiga
|
|
US11008344B2
(en)
|
2018-07-31 |
2021-05-18 |
Incyte Corporation |
Tricyclic heteroaryl compounds as STING activators
|
|
WO2020028566A1
(en)
|
2018-07-31 |
2020-02-06 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
US11691990B2
(en)
|
2018-08-16 |
2023-07-04 |
Eisai R&D Management Co., Ltd |
Salts of compounds and crystals thereof
|
|
EP3841112A1
(en)
|
2018-08-24 |
2021-06-30 |
Codiak BioSciences, Inc. |
Extracellular vesicles targeting dendritic cells and uses thereof
|
|
WO2020049534A1
(en)
*
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
CN110938104B
(zh)
*
|
2018-09-21 |
2024-07-12 |
上海迪诺医药科技有限公司 |
环状二核苷酸类似物、其药物组合物及应用
|
|
US11110106B2
(en)
|
2018-10-29 |
2021-09-07 |
Venenum Biodesign, LLC |
Sting agonists for treating bladder cancer and solid tumors
|
|
WO2020092127A1
(en)
|
2018-10-29 |
2020-05-07 |
Venenum Biodesign, LLC |
Novel sting agonists
|
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
|
WO2020117624A1
(en)
*
|
2018-12-07 |
2020-06-11 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
WO2020117623A1
(en)
*
|
2018-12-07 |
2020-06-11 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
US20220033431A1
(en)
*
|
2018-12-07 |
2022-02-03 |
Merck Sharp & Dohme Corp. |
Cyclic Di-Nucleotide Compounds as STING Agonists
|
|
WO2020146237A1
(en)
|
2019-01-07 |
2020-07-16 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
EP3901161B1
(en)
*
|
2019-01-10 |
2025-01-22 |
Shenzhen YING Biopharmaceutical Co., Ltd. |
Cyclic dinucleotide prodrug molecule, preparation method therefor and application thereof
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
EP3934757B1
(en)
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
BR112021018694A2
(pt)
|
2019-03-21 |
2021-11-30 |
Codiak Biosciences Inc |
Vesículas extracelulares para distribuição de vacina
|
|
US20240108747A1
(en)
|
2019-03-21 |
2024-04-04 |
Lonza Sales Ag |
Extracellular vesicle conjugates and uses thereof
|
|
TW202104214A
(zh)
|
2019-04-05 |
2021-02-01 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
化合物
|
|
WO2020227421A1
(en)
|
2019-05-09 |
2020-11-12 |
Aligos Therapeutics, Inc. |
Modified cyclic dinucleoside compounds as sting modulators
|
|
EP3994158A1
(en)
|
2019-07-03 |
2022-05-11 |
Codiak BioSciences, Inc. |
Extracellular vesicles targeting t cells and uses thereof
|
|
WO2021007160A1
(en)
|
2019-07-05 |
2021-01-14 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
US12435104B2
(en)
|
2019-07-25 |
2025-10-07 |
Beigene, Ltd. |
Cyclic dinucleotides as sting agonists
|
|
US20220305048A1
(en)
|
2019-08-26 |
2022-09-29 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
|
KR20220094221A
(ko)
|
2019-09-25 |
2022-07-05 |
코디악 바이오사이언시즈, 인크. |
종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀
|
|
MX2022003570A
(es)
|
2019-09-25 |
2022-07-11 |
Codiak Biosciences Inc |
Composiciones de vesícula extracelular.
|
|
WO2021062290A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Methods of producing extracellular vesicles
|
|
WO2021062058A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
US20240165144A1
(en)
*
|
2019-10-16 |
2024-05-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating innate immune signaling pathways
|
|
EP4077318B1
(en)
|
2019-12-18 |
2025-10-15 |
Ctxt Pty Ltd |
Benzimidazole dimers as modulators of sting
|
|
US12251449B2
(en)
|
2019-12-19 |
2025-03-18 |
William Marsh Rice University |
Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
|
|
CA3169523A1
(en)
|
2020-02-28 |
2021-09-02 |
Jaume Pons |
Transglutaminase-mediated conjugation
|
|
US20230114434A1
(en)
|
2020-03-13 |
2023-04-13 |
Codiak Biosciences, Inc. |
Extracellular vesicles for treating neurological disorders
|
|
JP2023518414A
(ja)
|
2020-03-20 |
2023-05-01 |
コディアック バイオサイエンシーズ， インコーポレイテッド |
治療のための細胞外小胞
|
|
US20230149560A1
(en)
|
2020-04-20 |
2023-05-18 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
|
MX2022014191A
(es)
|
2020-05-13 |
2022-12-07 |
Massachusetts Inst Technology |
Composiciones de microdispositivos polimericos y su uso en la inmunoterapia de cancer.
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
CN116056765A
(zh)
|
2020-08-07 |
2023-05-02 |
坦伯公司 |
反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
|
|
AU2021340623A1
(en)
|
2020-09-08 |
2023-04-13 |
The Board Of Regents Of The University Of Texas System |
Polyvalent STING activating compositions and uses thereof
|
|
US20240082389A1
(en)
|
2020-09-23 |
2024-03-14 |
Lonza Sales Ag |
Methods of producing extracellular vesicles
|
|
WO2022066883A1
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Extracellular vesicles comprising kras antigens and uses thereof
|
|
JP2023548310A
(ja)
|
2020-10-30 |
2023-11-16 |
アバクタ・ライフ・サイエンシーズ・リミテッド |
Ｆａｐ活性化血清半減期延長型治療用コンジュゲート
|
|
IL302390A
(en)
|
2020-11-09 |
2023-06-01 |
Takeda Pharmaceuticals Co |
Drug antibody conjugates
|
|
GB202018665D0
(en)
*
|
2020-11-26 |
2021-01-13 |
Provost Fellows And Scholars Of Trinity College Dublin |
Immunotherapy for cancer
|
|
EP4046634A1
(en)
*
|
2021-02-17 |
2022-08-24 |
Centre national de la recherche scientifique |
Serca2 modulators and their therapeutic uses
|
|
US20240209080A1
(en)
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
JP2024517131A
(ja)
|
2021-04-20 |
2024-04-19 |
アンスティテュ・クリー |
免疫療法における使用のための組成物及び方法
|
|
JP2024514707A
(ja)
|
2021-04-20 |
2024-04-02 |
アンスティテュ・クリー |
免疫療法における使用のための組成物及び方法
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
US12565681B2
(en)
*
|
2021-05-17 |
2026-03-03 |
China Medical University |
Method and a kit for predicting the susceptibility to stimulator of interferon genes (STING) agonists in a cancer patient
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
WO2023056468A1
(en)
|
2021-09-30 |
2023-04-06 |
Codiak Biosciences, Inc. |
Extracellular vesicle comprising cholesterol tagged sting-agonist
|
|
EP4687796A1
(en)
|
2023-04-05 |
2026-02-11 |
Massachusetts Institute of Technology |
Hybrid polymeric systems and methods of use thereof
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025202222A1
(en)
*
|
2024-03-25 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
|